Intraday mover · MRNA · Healthcare

Moderna Inc (MRNA) hit by 23.5% active-screen drop

The biotech stock drew heavy trading as short-term readings conflicted with a firmer today intraday price path.

Moderna Inc
Latest63.32 USD
1W move7.0%
Volume1.0x
TrendActive
Finance visual for Moderna showing biotechnology lab equipment beside a market-data screen.

Market update

What happened

Moderna Inc (MRNA) was flagged on the active-mover screen after dropping 23.5% to $133.32, with reported turnover of 97.3 million shares.

The confirming evidence is mixed. The today intraday price path showed Moderna at $150.72, up 4.2% from a $144.69 start, while Market Dynamics remained under pressure at -0.14 and Relative Strength stood at 31.2.

Weekly market data last showed a $63.32 close for the week ended Aug. 14, with returns of 7.0% over one week, 2.4% over four weeks, and 35.1% over twelve weeks.

Continue your research

Explore MRNA across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.Insider transactionsSee reported purchases and sales by company directors and executives.

MRNA coverage

Evidence context